Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
24 Cards in this Set
- Front
- Back
adrenal cortex divided into 3 zones
|
1. glomerulosa
2. fasiculata 3. reticularis |
|
cortisol levels peak
|
-in the morning
-gradually decrease throughout the day (if we averaged everyone) |
|
Cushing's syndrome
|
-the disease state resulting from a chronic excess of cortisol
|
|
causes of cushings syndrome
|
1. Cushing's disease- 65% (ACTH-secreting pituitary tumor)
2. adrenal adenoma 3. adrenal carcinoma 4. ectopic ACTH- ex. small cell lung 5. Ectopic CRG 6. ectopic adrenal receptors |
|
clinical features of cushings syndrome
|
1. truncal obesity
2. generalized obesity 3. plethora 4. moon face 5. HTN 6. bruising 7. purplish striae 8. muscle weakness 9. irreg menses 10. hirsutism 11. backache, osteoporosis |
|
pathogenesis of clinical features of cushings syndrome
|
1. Immunosuppression - glococorticoids suppress lymphocytes, decrease AB synthesis, dec PMN chemotaxis
2. mineralcorticoid effects: due to either or to concurrent overproduction of mineralcorticoids; can cause sodium retention, hypokalemia, HTN |
|
pathogenesis of clinical features of cushings syndrome- cont
|
Androgenic effects of byproducts of cortisol synthesis: hirsutism and virilization seen in some female patients
Miscellaneous: decreased intestinal calcium absorption, hypercalciuria and kidney stones, increased appetite, insomnia, alterations in mood, psychosis. |
|
cushings syndrome screening tests
|
1. overnight dexamethasone suppression test: 1 mg at bedtime. Serum cortisol at 8AM the next morning is normally <3.6 ug/dL
2. 24 hour urine free cortisol. Normal is <45-100 3. Salivary cortisol at midnight (should be very low; nml values depend on assay) |
|
DDx for cushings syndrome
|
1. plasma ACTH
2/ Serum potassium - often low in ectopic ACTH 3. 24-hr urine 17-ketosteroids may be very high (>40 mg/24 hr) in adrenal carcinoma |
|
Cushing's syndrome anatomic localization
|
-MRI of sella turcia
-CT scan of adrenals -Petrosal sinus sampling for plasma ACTH measurements in selected cases -octreotide nuclear scan to visualize somatostatin receptors found on carcnioid tumors, islet cell tumors and other sources of ectopic ACTH |
|
Treatment of cushing's syndrome
|
1. Surgery
2. Radiation therapy directed at tumor 3. Cabergoline- may suppress ACTH secretion from some pituitary tumors 4. adrenal enzyme blockade with metyrapone aminogluthethimide or ketoconazole 4. Anti-tumor chemo |
|
OTHER CAUSES OF CORTISOL NON-SUPPRESSIBILITY IN 1-MG OVERNIGHT TEST
|
1. stress or illness
2. active alcohol abuse 3. major depression 4. phenytoin therapy 5. massive obesity |
|
Nelson's Syndrome
|
-an invasive, ACTH-secreting tumor of the pituitary occuring after bilateral adrenalectomy for pituitary-dependent cushing's disease
|
|
Nelson's syndrome features
|
-post-adrenalectomy, pt on replacement doses of glucocorticoid
-avg time from adrenalectomy to dx: 3 yrs -intense hyperpigmentation -temporal visual field cuts, rapidly progressive -extra-ocular palsies -pituitary apoplexy -extremely high plasma ACTH concentration |
|
mgmt of Nelson;s syndrome
|
Prevention:
-primary tx of cushings disease directed at pituitary rather than adrenals -pituitary radiation at the time of adrenalectomy Treatment: -surgical hypophysectomy -radiotherapy -bromocriptine |
|
Primary adrenal insufficiency
|
Etiology: autoimmune, tbc, fungal, CMV, hemorrhage (increased by anticoagulants)
Symptoms: anorexia, weight loss, nausea, vomiting, hyperpigmentation, orthostasis Laboratory: hyponatremia, hyperkalemia, low cortisol, low aldosterone, high ACTH Poor cortisol response to IV cosyntropin (0.25 mg); normal peak cortisol >20 ug/dL |
|
Autoimmune Disorders Associated with Addison’s Disease
|
Hashimoto’s thyroiditis
Graves’ disease Type 1 diabetes mellitus Hypoparathyroidism Autoimmune gonadal failure Vitiligo Alopecia Pernicious anemia/atrophic gastritis |
|
treatment of primary adrenal insuffiency
|
1. glucocorticoids
2. mineralcorticoids 3. medic-alert or other id 4. increase dose of glucocorticoid for stress;give parenterally if needed 5. ? DHEA in some women |
|
secondary adrenal insufficiency
|
-due to hypothalamic/pituitary disease
-ssx: same as primary, except no hyperpigmentation -lab: hyponatremia, normokalemia, low cortisol, low ACTH, nl. aldosterone -blunt cortisol response to cosyntropin |
|
treatment of secondary adrenal insufficiency
|
-usually just glucocorticoids required
-aldosterone secretion is maintained by the renin-angiotensin system, so Florinef is not needed -? DHEA in some women -medic-alert or other ID -increase dose of glucocorticoid for stress; give parenterally if needed |
|
Adrenal incindentalomas
|
-an adrenal mass is coincidentally found in about 1-2% of abd CT scans
-most such masses are benign and do not secrete any hormonal product -determine which masses need to be surgically removed: 1. those which are endocrinologically active 2. those which as at high risk for malignancy |
|
pathology of adrenal incidentalomas
|
-non-functioning cortical adenoma
-cortisol-secreting adenoma -aldosterone-secreting adenoma -adrenocortical carcinoma -pheochryomocytoma -adrenal metastases from- non-adrenal tumor |
|
to r/o adrenaltumor
|
1.24-hr urine or plasma free metanephrines to R/O pheochromocytoma
2. 1-mg overnight dexamethasone supp. test to R/O cortisol-producing adenoma or carcinoma 3. High basal serum DHEA-S suggests androgen-producing tumor 4. Serum potassium and plasma aldosterone/PRA ratio to R/O hyperaldosteronism 5. May need to repeat evaluation yearly for 2-4 years to confidently exclude mild hyperfunction. |
|
if adrenal mass is non-functioning
|
1. Immediate surgical removal if mass > 4 cm in diameter (some suggest 5 or 6 cm)
2. If < 4 cm diameter, follow size with repeat CT scans at 4 and 12 months; remove if growing (25% of benign lesions grow slightly over 1 yr) 3. Masses in oncology patients may be adrenal metastases (esp. from lung, breast). CT-guided fine needle aspiration biopsy is useful in the diagnosis of metastases. |